Clinical Trial Update: Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anti-SARS-CoV-2 monoclonal antibodies for Long COVID and post-acute sequelae of SARS-CoV-2 infection. Results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid
• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Anti-SARS-CoV-2 monoclonal antibodies (SARS-CoV-2 neutralizing monoclonal antibodies)

Snippet

Sponsor: Michael Peluso, MD | Conditions: Long COVID, Post-Acute Sequela of COVID-19 | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-28